NasdaqGM - Delayed Quote USD

EDAP TMS S.A. (EDAP)

7.28

-0.12

(-1.62%)

At close: 4:00 PM EDT

EDAP Announces Final Results from HIFI Study Comparing Outcomes of Focal One® HIFU Versus Radical Prostatectomy to be Presented During Plenary Session at the Upcoming 119th American Urological Association (AUA) Annual Meeting

LYON, France, April 23, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced that final results from the HIFI Study, the largest clinical trial ever conducted comparing EDAP’s Focal One robotic high intensity focused ultrasound (HIFU) versus radical prostatectomy (RP) for the treatment of prostate cancer, will be presented during a plenary session at the 119th American Urological Association Annual Meeting (AUA 2024), which is taking place from May 3-

GlobeNewswire 3 days ago

EDAP
-1.62%
EDAP TMS S.A. (NASDAQ:EDAP) Just Reported Earnings, And Analysts Cut Their Target Price

EDAP TMS S.A. ( NASDAQ:EDAP ) last week reported its latest yearly results, which makes it a good time for investors to...

Simply Wall St. 27 days ago

EDAP
-1.62%
EDAP TMS S.A. (NASDAQ:EDAP) Q4 2023 Earnings Call Transcript

EDAP TMS S.A. (NASDAQ:EDAP) Q4 2023 Earnings Call Transcript March 27, 2024 EDAP TMS S.A. misses on earnings expectations. Reported EPS is $-0.15 EPS, expectations were $-0.04607. EDAP isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings and welcome to […]

Insider Monkey 28 days ago

EDAP
-1.62%
EDAP Reports Fourth Quarter and Full-Year 2023 Financial Results

Record Q4 2023 total revenue of EUR 19.6 million ($21.3 million USD) increased 24.8% over Q4 2022Record Q4 2023 HIFU revenue of EUR 7.5 million ($8.1 million USD), an increase of 38.8% over Q4 2022Record full-year 2023 total revenue of EUR 60.4 million ($65.4 million USD) increased 9.6% over full-year 2022Record full-year 2023 HIFU revenue of EUR 20.6 million ($22.3 million USD), an increase of 31.7% over full-year 2022Strong Q4 2023 U.S. Focal One® HIFU procedure growth of +136% year-over-year

GlobeNewswire 30 days ago

EDAP
-1.62%
EDAP to Announce Fourth Quarter and Full-Year 2023 Financial Results on March 27, 2024

Company to host conference call and webcast on Wednesday, March 27th at 8:30am EDT LYON, France, March 13, 2024 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the fourth quarter and full-year ended December 31, 2023, before the markets open on Wednesday, March 27th, 2024. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobe

GlobeNewswire last month

EDAP
-1.62%
EDAP to Present at the Oppenheimer 34th Annual Healthcare MedTech & Services Conference

LYON, France, March 6, 2024 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to deliver a virtual presentation and host 1x1 investor meetings at the Oppenheimer 34th Annual Healthcare MedTech & Services Conference, which is being held virtually from March 12-13, 2024. Presentation details: Date:Wednesday, March 13Time:9:20 – 9:50 AM ET Webcast:Link The live and archived webc

GlobeNewswire last month

EDAP
-1.62%
EDAP Announces FDA Breakthrough Device Designation for Focal One® in the Treatment of Deep Infiltrating Rectal Endometriosis

Focal One HIFU has potential to address large market impacting thousands of women each year LYON, France, March 4, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced today that its Focal One platform has been granted Breakthrough Device designation by the US Food and Drug Administration (FDA) for the treatment of deep infiltrating endometriosis (DIE). In June 2018, the FDA cleared Focal One Robotic Focal HIFU for the ablation of prostatic tissue. “R

GlobeNewswire last month

EDAP
-1.62%
EDAP Announces Record Preliminary Fourth Quarter and Full-Year 2023 Revenues

Record full-year 2023 preliminary unaudited revenue of EUR 60.4 million ($65.4 million USD), an increase of 9.6% over full-year 2022, driven by 31.7% HIFU growth Record Q4 2023 preliminary unaudited revenue of EUR 19.6 million ($21.3 million USD), an increase of 24.8% over for Q4 2022, driven by 38.8% HIFU growthStrong Q4 2023 U.S. Focal One® HIFU procedure growth of 136% year-over-year LYON, France, February 29, 2024 - EDAP TMS SA (Nasdaq: EDAP), a global leader in robotic energy-based therapie

GlobeNewswire last month

EDAP
-1.62%
EDAP Announces Completion of Enrollment in Phase 3 Study Evaluating Focal One HIFU Therapy for the Treatment of Deep Infiltrating Rectal Endometriosis

60 Patients Completed Enrollment in Under 9 Months Study Results Expected in the Second Half of 2024 LYON, France, February 1, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced today that it has completed enrollment in its Phase 3 study (Endo-HIFU-R2) evaluating Focal One High-Intensity Focused Ultrasound (HIFU) therapy for the treatment of deep infiltrating rectal endometriosis. The ongoing Phase 3 study (NCT05755958) is a comparative, randomized,

GlobeNewswire 2 months ago

EDAP
-1.62%
EDAP Announces Preliminary Fourth Quarter Record Focal One® System Sales and Placements

Company reports preliminary placement results of twelve Focal One Systems, inclusive of ten capital sales LYON, France, January 8, 2024 - EDAP TMS SA (Nasdaq: EDAP), (“EDAP”), the global leader in robotic energy-based therapies, announced today preliminary Focal One placement results for the fourth quarter of calendar year 2023. The Company experienced robust demand for its Focal One robotic HIFU technology, placing twelve Focal One systems, inclusive of ten capital sales. Additionally, it was a

GlobeNewswire 3 months ago

EDAP
-1.62%
EDAP Appoints Ken Mobeck, Global Chief Financial Officer, and Francois Dietsch, Global Chief Accounting Officer

LYON, France, January 2, 2024 - EDAP TMS SA (Nasdaq: EDAP), (“EDAP”), the global leader in robotic energy-based therapies, today announced that the Company has appointed Ken Mobeck as its Chief Financial Officer of EDAP worldwide, and Francois Dietsch as Global Chief Accounting Officer. Both appointments are effective as of January 1, 2024. “Over the past year, we have continued to align our organization in support of our strategic growth initiatives to build shareholder value by focusing on exp

GlobeNewswire 3 months ago

EDAP
-1.62%
Investing in EDAP TMS (NASDAQ:EDAP) five years ago would have delivered you a 155% gain

It hasn't been the best quarter for EDAP TMS S.A. ( NASDAQ:EDAP ) shareholders, since the share price has fallen 23% in...

Simply Wall St. 4 months ago

EDAP
-1.62%
EDAP Announces Positive Opinion for Reimbursement from the French National Authority for Health (HAS) for HIFU treatment of Prostate Cancer

Represents Key Milestone Toward Universal Coverage for Focal One HIFU in France LYON, France, December 12, 2023 - EDAP TMS SA (Nasdaq: EDAP), (“EDAP”), the global leader in robotic energy-based therapies, today announced that the French National Authority for Health (“HAS”) released a favorable recommendation for the reimbursement of high-intensity focused ultrasound (HIFU) therapy in the treatment of prostate cancer. The positive opinion from HAS is an important milestone along the regulatory p

GlobeNewswire 4 months ago

EDAP
-1.62%
EDAP Appoints Lance Willsey, M.S., M.D. to Board of Directors

LYON, France, December 6, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company” or “EDAP”), the global leader in robotic energy-based therapies, today announced the appointment of Lance Willsey, M.S., M.D. to its Board of Directors. Dr. Willsey replaces Dr. Argil Wheelock who has resigned as director of the Company. “I appreciate the opportunity to join the board of EDAP, where the company’s Focal One Robotic HIFU platform is changing the treatment paradigm in the management of prostate cancer,” sai

GlobeNewswire 4 months ago

EDAP
-1.62%
EDAP Receives 2023 Industry Category Award from the French National Institute for Intellectual Property (INPI) for Its Therapeutic Ultrasound Technology

LYON, France, November 30, 2023 - EDAP TMS SA (Nasdaq: EDAP), (“EDAP”), the global leader in robotic energy-based therapies, today announced that is has received the Industry Category Award from the French National Institute for Intellectual Property (INPI) based on the Company’s innovative therapeutic ultrasound technology. On November 23, 2023, the jury for the 2023 edition of the INPI Trophies honored five companies at an awards ceremony in Paris, which spanned five different categories: Expo

GlobeNewswire 4 months ago

EDAP
-1.62%
EDAP to Present at Piper Sandler’s 35th Annual Healthcare Conference

LYON, France, November 20, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to deliver a presentation and host 1x1 investor meetings at the Piper Sandler 35th Annual Healthcare Conference, which is being held November 28-30, 2023, in New York, New York. Presentation details: Date:Wednesday, November 29Time:11:00 – 11:25 AM ET Location:The Lotte New York PalaceWebcast:Li

GlobeNewswire 5 months ago

EDAP
-1.62%
EDAP TMS S.A.'s (NASDAQ:EDAP) top owners are individual investors with 56% stake, while 29% is held by institutions

Key Insights The considerable ownership by individual investors in EDAP TMS indicates that they collectively have a...

Simply Wall St. 5 months ago

EDAP
-1.62%
EDAP TMS S.A. (NASDAQ:EDAP) Q3 2023 Earnings Call Transcript

EDAP TMS S.A. (NASDAQ:EDAP) Q3 2023 Earnings Call Transcript November 9, 2023 EDAP TMS S.A. reports earnings inline with expectations. Reported EPS is $-0.11 EPS, expectations were $-0.11. Operator: Greetings and welcome to the Edap Tms third quarter 2023 earnings conference call. At this time, all participants are in a listen only mode. A brief […]

Insider Monkey 5 months ago

EDAP
-1.62%
EDAP Announces Third Quarter 2023 Financial Results

- Strong Q3 2023 U.S. Focal One® HIFU procedure growth of +150% year-over-year - - Record nine months HIFU revenues reflecting growing demand - - Two additional Focal One systems already placed in the fourth quarter - - Announces immunotherapy clinical research collaboration with Mount Sinai, Department of Urology - - Company to host conference call and webcast today, Thursday, November 9th at 8:30 am EDT - LYON, France, November 9, 2023 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic

GlobeNewswire 5 months ago

EDAP
-1.62%
EDAP to Present at the Jefferies London Healthcare Conference

LYON, France, November 6, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to deliver a presentation and host 1x1 investor meetings at the Jefferies London Healthcare Conference, which is being held November 14-16, 2023, in London. Presentation details: Date: Tuesday, November 14 Time: 9:00 – 9:25 AM GMT Webcast: Link The live and archived webcast of the presentation ca

GlobeNewswire 5 months ago

EDAP
-1.62%

Performance Overview

Return	EDAP	MSCI WORLD
YTD	+37.88%	+5.23%
1-Year	-33.21%	+19.56%
3-Year	-1.09%	0.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

EDAP TMS S.A. (EDAP)

EDAP Announces Final Results from HIFI Study Comparing Outcomes of Focal One® HIFU Versus Radical Prostatectomy to be Presented During Plenary Session at the Upcoming 119th American Urological Association (AUA) Annual Meeting

EDAP TMS S.A. (NASDAQ:EDAP) Just Reported Earnings, And Analysts Cut Their Target Price

EDAP TMS S.A. (NASDAQ:EDAP) Q4 2023 Earnings Call Transcript

EDAP Reports Fourth Quarter and Full-Year 2023 Financial Results

EDAP to Announce Fourth Quarter and Full-Year 2023 Financial Results on March 27, 2024

EDAP to Present at the Oppenheimer 34th Annual Healthcare MedTech & Services Conference

EDAP Announces FDA Breakthrough Device Designation for Focal One® in the Treatment of Deep Infiltrating Rectal Endometriosis

EDAP Announces Record Preliminary Fourth Quarter and Full-Year 2023 Revenues

EDAP Announces Completion of Enrollment in Phase 3 Study Evaluating Focal One HIFU Therapy for the Treatment of Deep Infiltrating Rectal Endometriosis

EDAP Announces Preliminary Fourth Quarter Record Focal One® System Sales and Placements

EDAP Appoints Ken Mobeck, Global Chief Financial Officer, and Francois Dietsch, Global Chief Accounting Officer

Investing in EDAP TMS (NASDAQ:EDAP) five years ago would have delivered you a 155% gain

EDAP Announces Positive Opinion for Reimbursement from the French National Authority for Health (HAS) for HIFU treatment of Prostate Cancer

EDAP Appoints Lance Willsey, M.S., M.D. to Board of Directors

EDAP Receives 2023 Industry Category Award from the French National Institute for Intellectual Property (INPI) for Its Therapeutic Ultrasound Technology

EDAP to Present at Piper Sandler’s 35th Annual Healthcare Conference

EDAP TMS S.A.'s (NASDAQ:EDAP) top owners are individual investors with 56% stake, while 29% is held by institutions

EDAP TMS S.A. (NASDAQ:EDAP) Q3 2023 Earnings Call Transcript

EDAP Announces Third Quarter 2023 Financial Results

EDAP to Present at the Jefferies London Healthcare Conference

Performance Overview